Kennedy's Disease, Spinal and Bulbar Muscular Atrophy
Conditions
Keywords
Motor Neuron, Androgen Receptor, Polyglutamine, X-Linked, Ligand Dependency, Spinal and Bulbar Muscular Atrophy, SBMA, Kennedy Disease
Brief summary
This study will determine if the drug dutasteride can improve weakness, mobility, functioning, nerve function, and quality of life in patients with spinal and bulbar muscular atrophy (SBMA). Patients with this inherited disease have an abnormal androgen receptor protein. The male hormones testosterone and dihydrotestosterone (DHT) bind to this abnormal receptor, causing damage to nerve cells that innervate muscle and leading to weakness. Dutasteride decreases DHT production. Lowering DHT levels may decrease the harmful effects of DHT to the nerves and improve strength in people with SBMA. Males 18 years of age and older with SBMA who have neurological symptoms and can walk 100 feet (with or without assistive devices) may be eligible for this study. Candidates are screened with a blood test and a review of their medical records and genetic studies. Participants undergo the following procedures: * Blood and urine tests, history and physical examination, assessment of muscle strength * Quality-of-life questionnaire * Tests to assess functional abilities, such walking up steps, keeping the head up while lying down, and other measures * Nerve conduction study and motor unit number estimation to assess nerve damage. A probe placed on the skin delivers small electrical impulses and wires taped to the skin record the impulses. * Quantitative muscle testing to measure strength. The subject pushes and pulls levers attached to a gauge. Strength is recorded by a computer. * Medication. Participants are divided into two groups. One group is given the study drug, dutasteride; the other receives a placebo (sugar pill). All participants take their assigned medication once a day for 24 months. * Follow-up evaluations. Every 6 months for 2 years, participants return to NIH to repeat the tests described above to determine the effects of the dutasteride. Nerve and quantitative muscle testing is not done at the 6- and 18-month visits. * In addition to their follow-up appointments here at the NIH every 6 months, participants will also have blood tests and a physical examination performed after 3, 9, 15 and 21 months of treatment by the patient's local physician.
Detailed description
Background: Spinal and bulbar muscular atrophy (SBMA) or Kennedy's disease is a slowly progressive, X-linked motor neuron disease for which there is currently no treatment. It is caused by a mutation in the androgen receptor that results in a polyglutamine repeat expansion. Recent animal studies have demonstrated that decreasing endogenous androgen levels leads to functional improvement and increased survival. Studies have also shown that high levels of 5 alpha-reductase, the enzyme that converts testosterone to the more potent dihydrotestosterone (DHT), are present in the ventral spinal cord, while low levels of this enzyme are found within skeletal muscle. Thus, by selectively decreasing levels of DHT with dutasteride, a 5 alpha-reductase inhibitor, it is hypothesized that there will be a selective protection of motor neurons, without the adverse effects of reducing the anabolic effects of androgen on muscle. Objective: This will be a phase II, double-blind, placebo-controlled trial examining the safety and efficacy of the 5 alpha-reductase inhibitor dutasteride in inhibiting the progression of neurodegeneration in patients with Kennedy's disease. Natural history data will also be obtained from the placebo control arm. Study Population: We aim to enroll 50 men with genetically confirmed Kennedy's disease. Design: Our objective is to examine the safety and efficacy of dutasteride given at a dose of 0.5 mg a day for 2 years in an outpatient setting. This will be a randomized, double-blind, placebo-controlled trial with 25 subjects in each arm. The subjects will be evaluated neurologically and endocrinologically every 6 months at the NIH Clinical Center. In addition to their clinical visits at the NIH, subjects will also be examined by their primary physician after 3, 9, 15, and 21 months of treatment. The primary objective is to examine the effects of dutasteride on inhibiting or reversing the rate of progression of weakness as measured by quantitative muscle testing. Following informed consent, patients will undergo an initial medical history and physical followed by testing of specific neurological and endocrinological measures over a two-day outpatient visit. Patients will provide blood samples for analysis of hormonal levels and extent of muscle damage every three months. In addition, at the initial, one-year, and two-year follow-up visits patients will have nerve conduction studies as well as quantitative and functional strength evaluation. Each patient will be randomized to the treatment or placebo arm and will be given a 3 month supply of the study drug or a matched placebo at each visit. In between clinic visits, the NIH clinical pharmacy will send an additional 3 month supply to each subject until the subsequent visit. Outcome Measures: The primary outcome measure used will be quantitative muscle testing (QMT). Secondary outcome measures include the Adult Myositis Assessment Tool (AMAT), 2-minute walk, a quality of life measure (Medical Outcomes Study 36-item Short Form Version 2, SF-36v2), neurophysiological testing (sensory nerve action potentials, and statistical motor unit number estimation). Changes in hormone levels (testosterone, dihydrotestosterone, androstenedione, estradiol), and creatine kinase levels will also be measured and correlated with changes in strength. Evaluation of disease severity and course as related to CAG repeat length and androgen levels will also be assessed. Future Directions: The results of this phase II study will assist us in developing a multi-center, double-blind, placebo-controlled phase III trial. In addition, natural history data will be obtained from the control arm that will be important in future clinical trials of SBMA.
Interventions
DRUGDutasteride
Dutasteride 0.5 mg/day
DRUGPlacebo
Matched placebo
Sponsors
National Institute of Neurological Disorders and Stroke (NINDS)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Genetically confirmed SBMA * Neurological symptoms of SBMA * Ability to ambulate 100 feet with or without the use of assistive devices * Willingness to participate in all aspects of trial design and follow-up * Male sex
Exclusion criteria
* Age less than 18 years * Female sex * A history of hypersensitivity to dutasteride or 5 alpha-reductase inhibitors. * Exposure to 5 alpha-reductase inhibitors, anti-androgens, testosterone, or steroids in the preceding 6 months * Patients who are taking potent cytochrome P450 3A4 (CYP3A4) inhibitors for over 4 weeks * Patients with any pre-existing liver disease * Alkaline phosphatase, gamma glutamyl transferase, or direct bilirubin greater than 1.5 times the upper limit of normal * Alanine aminotransferase or aspartate aminotransferase greater than 1.5 times upper limit of normal in subjects with normal creatine kinase levels * Creatinine greater than 1.5 times the upper limit of normal * Platelet count, white blood cell count or hemoglobin below the lower limit of normal * Other clinically significant medical disease that, in the judgment of the investigators, would expose the patient to undue risk of harm or prevent the patient from completing the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Muscle Strength Change From Baseline | 0, 12, and 24 months | Quantitative muscle assessment (QMA) was done with a fixed frame dynamometer, a strain gauge tensiometer, and a computer-aided acquisition system. Maximal voluntary isometric muscle contractions were measured twice, the average was calculated, and the results were summed over 22 muscle groups (11 on each side). The total force was scaled for body weight and expressed as percent change from baseline. Measurements were performed at 0, 12, and 24 months. The calculated percent changes at 12 and 24 months are shown. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Manual Muscle Testing, Change From Baseline. | 0, 12, and 24 months | Manual muscle testing was performed using a modified Medical Research Council (MRC) scale (0=worst, 5=best); the average muscle score was based on 22 muscle groups. |
| Adult Myopathy Assessment Tool, Change From Baseline | 0, 12, and 24 months | The Adult Myopathy Assessment Tool rates physical function and muscle endurance, with higher scores indicating better performance; it includes 7 timed functional tasks and 6 endurance tasks (0=worst, 45=best). |
| Timed 2-minute Walk, Change From Baseline | 0, 12, and 24 months | The subjects did the 2-minute walk in a 50-foot (15.2-meter) corridor three times, and the average distance was calculated. The subjects were allowed to use an assistive device and rest between the trials. |
| Swallow Score Average, Change From Baseline | 0, 12, and 24 months | Modified barium swallow studies were done at 0, 12, and 24 months. Twenty-five domains were assessed, and six were chosen for final analysis based on the abnormal findings in subjects evaluated at baseline: vallecular pooling and repeated-swallow, each assessed with thin liquids, purees, and solids (rated 1-4, abnormal to normal). |
| Bulbar Rating Scale, Change From Baseline | 0, 12, and 24 months | The Bulbar Rating Scale includes eight domains each rated on a 1-4 scale, abnormal to normal. The original 8-32 point scale was transformed to a 0-100% scale to represent the responses as percentages. |
| Sensory Nerve Action Potential Average, Change From Baseline | 0, 12, and 24 months | Nerve conduction studies were done on four sensory nerves (median, ulnar, radial, sural), and the amplitudes of the evoked responses were averaged. Loss of amplitude indicates impairment of conduction. |
| Creatine Kinase, Change From Baseline | 0, 12, and 24 months | Serum creatine kinase was determined in venous blood samples analyzed at the Department of Laboratory Medicine of the NIH Clinical Center. |
| Peroneal Compound Muscle Action Potential, Change From Baseline | 0, 12, and 24 months | Nerve conduction studies were done on the peroneal nerve, and the compound muscle action potential amplitude was determined. Loss of amplitude indicates impairment of conduction. |
| Motor Unit Nerve Estimation, Change From Baseline | 0, 12, and 24 months | Motor unit number estimation (MUNE) was done with a statistical MUNE program, on the abductor pollicis brevis. All subjects were evaluated on the right side unless severe atrophy produced very low compound muscle action potentials; in this case, the left side was investigated or the abductor digiti minimi was substituted. A decrease in MUNE indicates a loss of motor units. |
| Activities of Daily Living, Change From Baseline | 0, 12, and 24 months | Subjects rated their daily activity with a modified 9-question Activities of Daily Living (ADL) questionnaire (0-4, fully impaired to normal). |
| Medical Outcomes Study 36-item Short Form Version 2 (SF-36v2) Physical Component Summary, Change From Baseline | 0, 12, and 24 months | Subjects completed the Medical Outcomes Study Short Form Version 2 (SF-36v2), in which they rated their physical quality of life over the preceding 4 weeks. Raw SF-36v2 scores were converted to norm-based scales and component summaries using the scoring code provided by QualityMetric (mean=50, standard deviation (SD)=10). |
| Medical Outcomes Study 36-item Short Form Version 2 (SF-36v2) Mental Component Summary, Percent Change From Baseline | 0, 12, and 24 months | Subjects completed the Medical Outcomes Study Short Form Version 2 (SF-36v2), in which they rated their mental quality of life over the preceding 4 weeks. Raw SF-36v2 scores were converted to norm-based scales and component summaries using the scoring code provided by QualityMetric (mean=50, standard deviation (SD)=10), and percent change in the norm-based scale was calculated. |
| International Index for Erectile Function (IIEF), Change From Baseline | 0, 12, and 24 months | Sexual function was rated using the International Index of Erectile Function (IIEF). The total IIEF score (5-75, worst-best) was reported as the percent maximum (0-100%). |
| Median Compound Muscle Action Potential, Change From Baseline | 0, 12, and 24 months | Nerve conduction studies were done on the median motor nerve, and the compound muscle action potential amplitude was determined. Loss of amplitude indicates impairment of conduction. |
Countries
United States
Participant flow
Recruitment details
57 subjects were evaluated at the National Institutes of Health (NIH) Clinical Center.
Pre-assignment details
7 subjects were excluded on the basis of screening blood test abnormalities. 50 subjects were randomized.
Participants by arm
| Arm | Count |
|---|---|
| Placebo Matched placebo, one tablet daily | 25 |
| Dutasteride Dutasteride 500 micrograms, one tablet daily. | 25 |
| Total | 50 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Death | 0 | 1 |
| Overall Study | Physician Decision | 0 | 1 |
| Overall Study | Withdrawal by Subject | 2 | 2 |
Baseline characteristics
| Characteristic | Dutasteride | Placebo | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 4 Participants | 4 Participants | 8 Participants |
| Age, Categorical Between 18 and 65 years | 21 Participants | 21 Participants | 42 Participants |
| Age Continuous | 51.9 years STANDARD_DEVIATION 10.5 | 53.5 years STANDARD_DEVIATION 9.2 | 53.1 years STANDARD_DEVIATION 9.5 |
| Region of Enrollment United States | 25 participants | 25 participants | 50 participants |
| Sex: Female, Male Female | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Male | 25 Participants | 25 Participants | 50 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 23 / 25 | 23 / 25 |
| serious Total, serious adverse events | 2 / 25 | 5 / 25 |
Outcome results
Primary
Muscle Strength Change From Baseline
Quantitative muscle assessment (QMA) was done with a fixed frame dynamometer, a strain gauge tensiometer, and a computer-aided acquisition system. Maximal voluntary isometric muscle contractions were measured twice, the average was calculated, and the results were summed over 22 muscle groups (11 on each side). The total force was scaled for body weight and expressed as percent change from baseline. Measurements were performed at 0, 12, and 24 months. The calculated percent changes at 12 and 24 months are shown.
Time frame: 0, 12, and 24 months
Population: The participants analyzed were those who were available for analysis at 12 and 24 months.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Muscle Strength Change From Baseline | Muscle Strength Change From Baseline at 12 Months | -2.2 percent change | Standard Deviation 9.4 |
| Placebo | Muscle Strength Change From Baseline | Muscle Strength Change From Baseline at 24 Months | -4.5 percent change | Standard Deviation 13.5 |
| Dutasteride | Muscle Strength Change From Baseline | Muscle Strength Change From Baseline at 12 Months | 3.1 percent change | Standard Deviation 27.1 |
| Dutasteride | Muscle Strength Change From Baseline | Muscle Strength Change From Baseline at 24 Months | 1.3 percent change | Standard Deviation 24.2 |
p-value: 0.28Generalized estimating equation model
Secondary
Activities of Daily Living, Change From Baseline
Subjects rated their daily activity with a modified 9-question Activities of Daily Living (ADL) questionnaire (0-4, fully impaired to normal).
Time frame: 0, 12, and 24 months
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Activities of Daily Living, Change From Baseline | Activities of Daily Living, Change at 12 months | 0.4 units on a scale | Standard Deviation 2.3 |
| Placebo | Activities of Daily Living, Change From Baseline | Activities of Daily Living, Change at 24 months | 1.2 units on a scale | Standard Deviation 3.3 |
| Dutasteride | Activities of Daily Living, Change From Baseline | Activities of Daily Living, Change at 12 months | 0.4 units on a scale | Standard Deviation 2.8 |
| Dutasteride | Activities of Daily Living, Change From Baseline | Activities of Daily Living, Change at 24 months | 1.1 units on a scale | Standard Deviation 4.2 |
p-value: 1Generalized estimating equation model
Secondary
Adult Myopathy Assessment Tool, Change From Baseline
The Adult Myopathy Assessment Tool rates physical function and muscle endurance, with higher scores indicating better performance; it includes 7 timed functional tasks and 6 endurance tasks (0=worst, 45=best).
Time frame: 0, 12, and 24 months
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Adult Myopathy Assessment Tool, Change From Baseline | Adult Myopathy Assessment Tool, Change at 12 mos. | -2.2 units on a scale | Standard Deviation 3.7 |
| Placebo | Adult Myopathy Assessment Tool, Change From Baseline | Adult Myopathy Assessment Tool, Change at 24 mos. | -2.8 units on a scale | Standard Deviation 4.2 |
| Dutasteride | Adult Myopathy Assessment Tool, Change From Baseline | Adult Myopathy Assessment Tool, Change at 12 mos. | -0.7 units on a scale | Standard Deviation 2.4 |
| Dutasteride | Adult Myopathy Assessment Tool, Change From Baseline | Adult Myopathy Assessment Tool, Change at 24 mos. | -1.5 units on a scale | Standard Deviation 3.9 |
p-value: 0.13Generalized estimating equation model
Secondary
Bulbar Rating Scale, Change From Baseline
The Bulbar Rating Scale includes eight domains each rated on a 1-4 scale, abnormal to normal. The original 8-32 point scale was transformed to a 0-100% scale to represent the responses as percentages.
Time frame: 0, 12, and 24 months
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Bulbar Rating Scale, Change From Baseline | Bulbar Rating Scale, Change at 12 months | 5.7 percentage of maximum score | Standard Deviation 6.7 |
| Placebo | Bulbar Rating Scale, Change From Baseline | Bulbar Rating Scale, Change at 24 months | 6.4 percentage of maximum score | Standard Deviation 5.8 |
| Dutasteride | Bulbar Rating Scale, Change From Baseline | Bulbar Rating Scale, Change at 12 months | 2.6 percentage of maximum score | Standard Deviation 6.8 |
| Dutasteride | Bulbar Rating Scale, Change From Baseline | Bulbar Rating Scale, Change at 24 months | 3.9 percentage of maximum score | Standard Deviation 4.6 |
p-value: 0.08Generalized estimating equation model
Secondary
Creatine Kinase, Change From Baseline
Serum creatine kinase was determined in venous blood samples analyzed at the Department of Laboratory Medicine of the NIH Clinical Center.
Time frame: 0, 12, and 24 months
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Creatine Kinase, Change From Baseline | Creatine kinase change at 12 months | -36 Units/liter | Standard Deviation 360 |
| Placebo | Creatine Kinase, Change From Baseline | Creatine kinase change at 24 months | -19 Units/liter | Standard Deviation 494 |
| Dutasteride | Creatine Kinase, Change From Baseline | Creatine kinase change at 12 months | -32 Units/liter | Standard Deviation 375 |
| Dutasteride | Creatine Kinase, Change From Baseline | Creatine kinase change at 24 months | -62 Units/liter | Standard Deviation 472 |
p-value: 0.86Generalized estimating equation model
Secondary
International Index for Erectile Function (IIEF), Change From Baseline
Sexual function was rated using the International Index of Erectile Function (IIEF). The total IIEF score (5-75, worst-best) was reported as the percent maximum (0-100%).
Time frame: 0, 12, and 24 months
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | International Index for Erectile Function (IIEF), Change From Baseline | IIEF, Change at 12 months | -2.4 percent of maximum score | Standard Deviation 10.2 |
| Placebo | International Index for Erectile Function (IIEF), Change From Baseline | IIEF, Change at 24 months | -0.3 percent of maximum score | Standard Deviation 16.4 |
| Dutasteride | International Index for Erectile Function (IIEF), Change From Baseline | IIEF, Change at 12 months | -2.1 percent of maximum score | Standard Deviation 11.6 |
| Dutasteride | International Index for Erectile Function (IIEF), Change From Baseline | IIEF, Change at 24 months | -3.5 percent of maximum score | Standard Deviation 6.9 |
p-value: 0.61Generalized estimating equation model
Secondary
Manual Muscle Testing, Change From Baseline.
Manual muscle testing was performed using a modified Medical Research Council (MRC) scale (0=worst, 5=best); the average muscle score was based on 22 muscle groups.
Time frame: 0, 12, and 24 months
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Manual Muscle Testing, Change From Baseline. | Manual Muscle Testing, Change at 12 months | 0.04 MRC units on a scale | Standard Deviation 0.7 |
| Placebo | Manual Muscle Testing, Change From Baseline. | Manual Muscle Testing, Change at 24 months | 0.02 MRC units on a scale | Standard Deviation 0.7 |
| Dutasteride | Manual Muscle Testing, Change From Baseline. | Manual Muscle Testing, Change at 12 months | -0.25 MRC units on a scale | Standard Deviation 0.8 |
| Dutasteride | Manual Muscle Testing, Change From Baseline. | Manual Muscle Testing, Change at 24 months | 0.01 MRC units on a scale | Standard Deviation 0.5 |
Comparison: Comparison of changes from baseline in manual muscle testing results.p-value: 0.47Generalized estimating equation model
Secondary
Median Compound Muscle Action Potential, Change From Baseline
Nerve conduction studies were done on the median motor nerve, and the compound muscle action potential amplitude was determined. Loss of amplitude indicates impairment of conduction.
Time frame: 0, 12, and 24 months
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Median Compound Muscle Action Potential, Change From Baseline | Median Motor Action Potential, Change at 12 months | 0.04 mVolts | Standard Deviation 2.15 |
| Placebo | Median Compound Muscle Action Potential, Change From Baseline | Median Motor Action Potential, Change at 24 months | -0.24 mVolts | Standard Deviation 1.84 |
| Dutasteride | Median Compound Muscle Action Potential, Change From Baseline | Median Motor Action Potential, Change at 12 months | 0.52 mVolts | Standard Deviation 2.63 |
| Dutasteride | Median Compound Muscle Action Potential, Change From Baseline | Median Motor Action Potential, Change at 24 months | 0.24 mVolts | Standard Deviation 1.89 |
p-value: 0.37Generalized estimating equation model
Secondary
Medical Outcomes Study 36-item Short Form Version 2 (SF-36v2) Mental Component Summary, Percent Change From Baseline
Subjects completed the Medical Outcomes Study Short Form Version 2 (SF-36v2), in which they rated their mental quality of life over the preceding 4 weeks. Raw SF-36v2 scores were converted to norm-based scales and component summaries using the scoring code provided by QualityMetric (mean=50, standard deviation (SD)=10), and percent change in the norm-based scale was calculated.
Time frame: 0, 12, and 24 months
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Medical Outcomes Study 36-item Short Form Version 2 (SF-36v2) Mental Component Summary, Percent Change From Baseline | SF-36v2 Mental Component Sum., Change at 12 mos. | 0.6 percent change | Standard Deviation 11.1 |
| Placebo | Medical Outcomes Study 36-item Short Form Version 2 (SF-36v2) Mental Component Summary, Percent Change From Baseline | SF-36v2 Mental Component Sum., Change at 24 mos. | 3.3 percent change | Standard Deviation 9.3 |
| Dutasteride | Medical Outcomes Study 36-item Short Form Version 2 (SF-36v2) Mental Component Summary, Percent Change From Baseline | SF-36v2 Mental Component Sum., Change at 12 mos. | 0.1 percent change | Standard Deviation 7.9 |
| Dutasteride | Medical Outcomes Study 36-item Short Form Version 2 (SF-36v2) Mental Component Summary, Percent Change From Baseline | SF-36v2 Mental Component Sum., Change at 24 mos. | -3.2 percent change | Standard Deviation 10.2 |
p-value: 0.033t-test, 2 sided
Secondary
Medical Outcomes Study 36-item Short Form Version 2 (SF-36v2) Physical Component Summary, Change From Baseline
Subjects completed the Medical Outcomes Study Short Form Version 2 (SF-36v2), in which they rated their physical quality of life over the preceding 4 weeks. Raw SF-36v2 scores were converted to norm-based scales and component summaries using the scoring code provided by QualityMetric (mean=50, standard deviation (SD)=10).
Time frame: 0, 12, and 24 months
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Medical Outcomes Study 36-item Short Form Version 2 (SF-36v2) Physical Component Summary, Change From Baseline | SF-36v2 Physical Component Sum., Change at 12 mos. | -0.9 percent change | Standard Deviation 6.5 |
| Placebo | Medical Outcomes Study 36-item Short Form Version 2 (SF-36v2) Physical Component Summary, Change From Baseline | SF-36v2 Physical Component Sum., Change at 24 mos. | -3.6 percent change | Standard Deviation 8.4 |
| Dutasteride | Medical Outcomes Study 36-item Short Form Version 2 (SF-36v2) Physical Component Summary, Change From Baseline | SF-36v2 Physical Component Sum., Change at 12 mos. | 2.5 percent change | Standard Deviation 5.9 |
| Dutasteride | Medical Outcomes Study 36-item Short Form Version 2 (SF-36v2) Physical Component Summary, Change From Baseline | SF-36v2 Physical Component Sum., Change at 24 mos. | 2.1 percent change | Standard Deviation 6.1 |
p-value: 0.014Generalized estimating equation model
Secondary
Motor Unit Nerve Estimation, Change From Baseline
Motor unit number estimation (MUNE) was done with a statistical MUNE program, on the abductor pollicis brevis. All subjects were evaluated on the right side unless severe atrophy produced very low compound muscle action potentials; in this case, the left side was investigated or the abductor digiti minimi was substituted. A decrease in MUNE indicates a loss of motor units.
Time frame: 0, 12, and 24 months
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Motor Unit Nerve Estimation, Change From Baseline | Motor Unit Nerve Estimation, Change at 12 months | -4.2 motor unit number | Standard Deviation 18.9 |
| Placebo | Motor Unit Nerve Estimation, Change From Baseline | Motor Unit Nerve Estimation, Change at 24 months | -2.2 motor unit number | Standard Deviation 23.3 |
| Dutasteride | Motor Unit Nerve Estimation, Change From Baseline | Motor Unit Nerve Estimation, Change at 12 months | -4.2 motor unit number | Standard Deviation 18.7 |
| Dutasteride | Motor Unit Nerve Estimation, Change From Baseline | Motor Unit Nerve Estimation, Change at 24 months | -2.6 motor unit number | Standard Deviation 17.5 |
p-value: 0.99Generalized estimating equation model
Secondary
Peroneal Compound Muscle Action Potential, Change From Baseline
Nerve conduction studies were done on the peroneal nerve, and the compound muscle action potential amplitude was determined. Loss of amplitude indicates impairment of conduction.
Time frame: 0, 12, and 24 months
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Peroneal Compound Muscle Action Potential, Change From Baseline | Peroneal Motor Action Potential, Change at 12 mos. | 0.16 mVolts | Standard Deviation 1.07 |
| Placebo | Peroneal Compound Muscle Action Potential, Change From Baseline | Peroneal Motor Action Potential, Change at 24 mos. | 0.15 mVolts | Standard Deviation 1.37 |
| Dutasteride | Peroneal Compound Muscle Action Potential, Change From Baseline | Peroneal Motor Action Potential, Change at 12 mos. | 0.02 mVolts | Standard Deviation 0.84 |
| Dutasteride | Peroneal Compound Muscle Action Potential, Change From Baseline | Peroneal Motor Action Potential, Change at 24 mos. | 0.04 mVolts | Standard Deviation 0.81 |
p-value: 0.65Generalized estimating equation model
Secondary
Sensory Nerve Action Potential Average, Change From Baseline
Nerve conduction studies were done on four sensory nerves (median, ulnar, radial, sural), and the amplitudes of the evoked responses were averaged. Loss of amplitude indicates impairment of conduction.
Time frame: 0, 12, and 24 months
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Sensory Nerve Action Potential Average, Change From Baseline | Sensory Nerve Action Potential, Change at 12 mos. | 0 microVolts | Standard Deviation 1 |
| Placebo | Sensory Nerve Action Potential Average, Change From Baseline | Sensory Nerve Action Potential, Change at 24 mos. | 0 microVolts | Standard Deviation 1 |
| Dutasteride | Sensory Nerve Action Potential Average, Change From Baseline | Sensory Nerve Action Potential, Change at 12 mos. | 0 microVolts | Standard Deviation 1 |
| Dutasteride | Sensory Nerve Action Potential Average, Change From Baseline | Sensory Nerve Action Potential, Change at 24 mos. | 0 microVolts | Standard Deviation 1 |
p-value: 0.73Generalized estimating equation model
Secondary
Swallow Score Average, Change From Baseline
Modified barium swallow studies were done at 0, 12, and 24 months. Twenty-five domains were assessed, and six were chosen for final analysis based on the abnormal findings in subjects evaluated at baseline: vallecular pooling and repeated-swallow, each assessed with thin liquids, purees, and solids (rated 1-4, abnormal to normal).
Time frame: 0, 12, and 24 months
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Swallow Score Average, Change From Baseline | Swallow Score Average, Change at 12 months | -0.25 units on a scale | Standard Deviation 0.4 |
| Placebo | Swallow Score Average, Change From Baseline | Swallow Score Average, Change at 24 months | -0.53 units on a scale | Standard Deviation 0.5 |
| Dutasteride | Swallow Score Average, Change From Baseline | Swallow Score Average, Change at 12 months | 0.06 units on a scale | Standard Deviation 0.6 |
| Dutasteride | Swallow Score Average, Change From Baseline | Swallow Score Average, Change at 24 months | -0.14 units on a scale | Standard Deviation 0.5 |
p-value: 0.11Generalized estimating equation model
Secondary
Timed 2-minute Walk, Change From Baseline
The subjects did the 2-minute walk in a 50-foot (15.2-meter) corridor three times, and the average distance was calculated. The subjects were allowed to use an assistive device and rest between the trials.
Time frame: 0, 12, and 24 months
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Timed 2-minute Walk, Change From Baseline | Timed 2-minute Walk, Change at 12 months | 8.1 meters | Standard Deviation 29.8 |
| Placebo | Timed 2-minute Walk, Change From Baseline | Timed 2-minute Walk, Change at 24 months | 2.2 meters | Standard Deviation 32.6 |
| Dutasteride | Timed 2-minute Walk, Change From Baseline | Timed 2-minute Walk, Change at 12 months | -0.8 meters | Standard Deviation 28.5 |
| Dutasteride | Timed 2-minute Walk, Change From Baseline | Timed 2-minute Walk, Change at 24 months | -1.6 meters | Standard Deviation 29.6 |
p-value: 0.46Generalized estimating equation model